Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome
Reproductive Sciences · 2025-07 · 32 (7) · 2453-2466
DOI: 10.1007/s43032-025-01885-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Sciences, online erschienen am 23.06.2025. Verfasst von Zeynep Ece Utkan Korun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yeditepe University Kozyatagi Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Dehydroepiandrosterone, Ovary, Plant Extracts. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Koc University.
Abstract (Originalsprache)
Alchemilla vulgaris has traditionally been used to treat gynecologic diseases. The anti-inflammatory and vasorelaxant effects of the extract of A. vulgaris (AVE) have been reported in previous studies. This study aimed to investigate the effects of A. vulgaris on PCOS, one of the most common metabolic disorders in adult women of reproductive age, accompanied by inflammation and vascular endothelial dysfunction, in an experimental animal model. Three groups of prepubertal female Wistar rats were established: PCOS, Control, and PCOS + AVE groups. Subcutaneous dehydroepiandrosterone (DHEA) was administered for 35 days to the PCOS and PCOS + AVE groups. The rats in the PCOS + AVE group were orally administered AVE (50 mg/100 g bw/day) for 35 days. Systemic blood pressure, vascular endothelial function, ovarian morphology, and endocrine biomarker levels were measured at the end of the experiment. TNF-α levels were also evaluated in the thoracic aorta and ovaries. Hormonal imbalances, ovarian morphological changes, and endothelial dysfunction were observed in the PCOS group, which returned to the controls after AVE treatment. Furthermore, AVE attenuated the aortic and ovarian levels of TNF-α in the PCOS group. Our study suggests that AVE may have beneficial effects in the treatment of PCOS due to its anti-inflammatory and vasculoprotective properties. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Yeditepe University Kozyatagi Hospital, Istanbul, Turkey.
- Institute of Health Sciences, Department of Stem Cell, Kocaeli University, Kocaeli, Turkey.
- Faculty of Medicine, Department of Pharmacology, Kocaeli University, Kocaeli, Turkey.
- Faculty of Medicine, Department of Histology and Embryology, Kocaeli University, Kocaeli, Turkey.
- Faculty of Dentistry, Department of Basic Medical Sciences, Kocaeli Health and Technology University, Kocaeli, Turkey.
- Faculty of Medicine, Department of Biochemistry, Kocaeli University, Kocaeli, Turkey.
ORCID-Profile: Zeynep Ece Utkan Korun, Semil Selcen Gocmez, Selenay Furat, Kubra Kavram Sarihan, Fatma Ceyla Eraldemir, Huseyin Askin Akpulat, Deniz Sahin, Sule Yildiz
Förderung
- Koc University
Zitieren
APA
Korun, Z. E. U., Gocmez, S. S., Furat, S., Sarihan, K. K., Eraldemir, F. C., Akpulat, H. A., Sahin, D., & Yildiz, S. (2025). Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome. Reproductive Sciences, 32(7), 2453-2466. https://doi.org/10.1007/s43032-025-01885-9
Vancouver
Korun ZEU, Gocmez SS, Furat S, Sarihan KK, Eraldemir FC, Akpulat HA, et al. Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome. Reproductive Sciences. 2025;32(7):2453-2466. doi:10.1007/s43032-025-01885-9
BibTeX
@article{Korun2025,
author = {Korun, Zeynep Ece Utkan and Gocmez, Semil Selcen and Furat, Selenay and Sarihan, Kubra Kavram and Eraldemir, Fatma Ceyla and Akpulat, Huseyin Askin and Sahin, Deniz and Yildiz, Sule},
title = {Beneficial Effects of Alchemilla vulgaris in DHEA-Induced Rat Model of Polycystic Ovary Syndrome},
journal = {Reproductive Sciences},
year = {2025},
volume = {32},
number = {7},
pages = {2453--2466},
doi = {10.1007/s43032-025-01885-9}
}
EUVIMED